A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-31 and is reviewed periodically as new material appears.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
High-performance thin-layer chromatography (HPTLC) serves as an extension of thin-layer chromatography (TLC), offering robustness, simplicity, speed, and efficiency in the quantitative analysis of compounds. This TLC-based analytical technique enhances compound resolution for quantitative analysis. Some of these improvements involve employing higher-quality TLC plates with finer particle sizes in the stationary phase, leading to improved resolution. Additionally, the separation can be further refined through repeated plate development using a multiple development device. As a result, HPTLC provides superior resolution and lower Limit of Detection (LODs).
== External links == "Huffingtonpost Israel-Wolf-Prizes 2012". Huffington Post. 10 January 2012. "Jerusalempost Israel-Wolf-Prizes 2013". December 2010. "Jerusalempost Israel-Wolf-Prizes 2014". 16 January 2014. Jerusalempost Israel-Wolf-Prizes 2016 Jerusalempost Israel-Wolf-Prizes 2017 Jerusalempost Wolf-Prizes 2018 Wolf Prize 2019
In the deep-sea genus Stauroteuthis, the suckers in most species have been altered into photophores which are believed to fool prey by directing them to the mouth, making them one of the few bioluminescent octopuses.
An epitope, () also known as antigenic determinant, is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells. The part of an antibody that binds to the epitope is called a paratope. Although epitopes are usually non-self proteins, sequences derived from the host that can be recognized (as in the case of autoimmune diseases) are also epitopes. The epitopes of protein antigens are divided into two categories, conformational epitopes and linear epitopes, based on their structure and interaction with the paratope. Conformational and linear epitopes interact with the paratope based on the 3-D conformation adopted by the epitope, which is determined by the surface features of the involved epitope residues and the shape or tertiary structure of other segments of the antigen. A conformational epitope is formed by the 3-D conformation adopted by the interaction of discontiguous amino acid residues. In contrast, a linear epitope is formed by the 3-D conformation adopted by the interaction of contiguous amino acid residues. A linear epitope is not determined solely by the primary structure of the involved amino acids. Residues that flank such amino acid residues, as well as more distant amino acid residues of the antigen affect the ability of the primary structure residues to adopt the epitope's 3-D conformation. 90% of epitopes are conformational.
Sources: en.wikipedia.org
The following twenty years saw a veritable explosion in the number of stability constants that were determined. Relationships, such as the Irving-Williams series were discovered. The calculations were done by hand using the so-called graphical methods. The mathematics underlying the methods used in this period are summarised by Rossotti and Rossotti. The next key development was the use of a computer program, LETAGROP to do the calculations. This permitted the examination of systems too complicated to be evaluated by means of hand-calculations. Subsequently, computer programs capable of handling complex equilibria in general, such as SCOGS and MINIQUAD were developed so that today the determination of stability constants has almost become a "routine" operation. Values of thousands of stability constants can be found in two commercial databases.
== Further reading == Slater, Anna G.; Cooper, Andrew I. (2015-05-29). "Function-led design of new porous materials". Science. 348 (6238) aaa8075. doi:10.1126/science.aaa8075. PMID 26023142. Satoh, Yusuke; Matsuno, Hirohiko; Yamamato, Takuya; Tajima, Kenji; Isono, Takuya; Satoh, Toshifumi (2017). "Synthesis of Well-Defined Three- and Four-Armed Cage-Shaped Polymers via "Topological Conversion" from Trefoil- and Quatrefoil-Shaped Polymers". Macromolecules. 50 (1): 97–106. Bibcode:2017MaMol..50...97S. doi:10.1021/acs.macromol.6b02316. Mato, Yoshinobu; Honda, Kohei; Tajima, Kenji; Yamamato, Takuya; Isono, Takuya; Satoh, Toshifumi (2019). "A versatile synthetic strategy for macromolecular cages: intramolecular consecutive cyclization of star-shaped polymers". Chemical Science. 10 (2): 440–446. doi:10.1039/C8SC04006K. PMC 6335864. PMID 30746091. Lee, Taeheon; Oh, Joongsuk; Jeong, Jonghwa; Jung, Haeji; Huh, June; Chang, Taihyun; Paik, Hyun-jong (2016-05-24). "Figure-Eight-Shaped and Cage-Shaped Cyclic Polystyrenes". Macromolecules. 49 (10): 3672–3680. Bibcode:2016MaMol..49.3672L. doi:10.1021/acs.macromol.6b00093. ISSN 0024-9297.
=== Legal status === The FDA granted the application for pegcetacoplan orphan drug designation. In October 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Aspaveli, intended for the treatment of adults with paroxysmal nocturnal hemoglobinuria. The applicant for this medicinal product is Swedish Orphan Biovitrum AB (publ). Pegcetacoplan was approved for the treatment of paroxysmal nocturnal hemoglobinuria in the European Union in December 2021. FDA approved Syfovre for the treatment of geographic atrophy secondary to age-related macular degeneration (ARMD) in February 2023. In June 2024, the CHMP recommended the refusal of a marketing authorization for Syfovre, a medicine intended for the treatment of geographic atrophy caused by age-related macular degeneration. The manufacturer requested a re-examination in July 2024. In September 2024, the CHMP continued to refuse a marketing authorization after a re-examination.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.